KRAS and lung adenocarcinoma: Canakinumab, a human anti-IL-1β monoclonal antibody extensively used in inflammatory diseases, has been used in the treatment of various cancers, including lung cancer [203, 204], breast cancer [205], colon cancer, and other tumors [206].Furthermore, Yuan et al. demonstrated that the inhibition of IL-1β with canakinumab significantly reduced tumor growth in K-ras-mutant lung adenocarcinoma by reshaping the TME [133].